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The rapid development of genomic sequencing technologies has decreased
the cost of genetic analysis to the extent that it seems plausible that genomescale sequencing could have widespread availability in pediatric care.
Genomic sequencing provides a powerful diagnostic modality for patients
who manifest symptoms of monogenic disease and an opportunity to detect
health conditions before their development. However, many technical,
clinical, ethical, and societal challenges should be addressed before such
technology is widely deployed in pediatric practice. This article provides
an overview of the Newborn Sequencing in Genomic Medicine and Public
Health Consortium, which is investigating the application of genome-scale
sequencing in newborns for both diagnosis and screening.

Universal newborn screening (NBS)
is an extraordinarily successful
public health program, preventing
morbidity and mortality through
early diagnosis and management of
conditions including rare inborn errors
of metabolism.1 Conditions such as
phenylketonuria are not clinically
evident at birth but lead to significant
irreversible harm or death if not
treated promptly.2 NBS has saved
countless lives and vastly improved the
quality of children’s lives by allowing
timely therapeutic interventions, and
technological advances such as the use
of tandem mass spectrometry
(MS/MS) have played a significant
role in expansion of NBS.3,4
The ability to analyze many or all
genes in the genome simultaneously
provides new opportunities for
genomic medicine. The capacity of
genome-scale sequencing for disease

gene discovery is well documented,5
and it is increasingly being applied
as a diagnostic test in children with
suspected monogenic disorders.6,7
The tangible potential of genomic
sequencing more broadly in medicine,
as part of “personalized” or “precision”
medicine,8 was foreshadowed in 1990
by Walter Gilbert, who extrapolated
from the exponential growth of DNA
sequencing that all newborns would
have their genomes sequenced by
2030 or 2040. The idea that genomic
sequencing will someday become part
of the standard care of newborns is
carried forward into today’s dialogue:
As we learn more about effective
interventions for genetic risk factors, and
recognize that interventions early in life
provide significant advantages, it will
become more and more compelling to
determine this information at birth.
—F. S. Collins, The Language of Life: DNA
and the Revolution in Personalized Medicine.
New York: Harper Perennial (2010)
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Such predictions raise important
questions: Could genomic sequencing
become part of the universal
standard NBS performed by each
state, replacing conventional
biochemical testing, or could it be
offered as an optional supplement?
How would sequencing be paid for,
and how would parental informed
consent be obtained? What impact
would genomic sequencing in
newborns have on children’s health?
What implications would it have
for issues such as protecting an
autonomous person’s right not to
know?
In the diagnostic setting, the goal
of genome-scale sequencing is to
identify genetic variants that provide
a molecular etiology for the patient’s
symptoms. All other variants are
considered incidental findings (or
secondary findings when discovered
through intentional analysis).9 These
additional findings differ widely with
regard to predictive capacity and
clinical actionability. Not surprisingly,
there is disagreement about how
much genomic information should
be routinely returned in a pediatric
setting,10–14 and children and their
parents are likely to express unique
preferences.15,16 Central challenges
for clinical implementation thus
revolve around the boundaries of
professional responsibility and
individual or parental choice, best
practices for informed consent and
determining parental preferences,
standards regarding the types of
findings that should be reported,
long-term storage of genomic
information so that it can be acted on
at the appropriate time, and whether
and how genomic data should be
reanalyzed and reinterpreted.
The application of genomic
sequencing in asymptomatic
newborns intensifies many of these
challenges and exposes deep societal
questions about nonmaleficence,
beneficence, autonomy, and the
preservation of each child’s open
future.17–19 Additionally, the

economics of such screening must be
considered before implementation
on a population level. Although
the technical features needed for
rapid genomic sequencing appear
feasible, interpretation of each
asymptomatic person’s variant
profile will remain labor intensive for
the foreseeable future, and clinically
useful prediction of future disease
may prove elusive. Recognizing these
trends, the Eunice Kennedy Shriver
National Institute of Child Health
and Human Development (NICHD),
National Human Genome Research
Institute, and the Office of Rare
Disease Research held a workshop in
December 2010 to identify elements
of a trans–National Institutes of
Health research agenda that could
inform the possible application of
new genomic technologies to NBS
and child health (https://www.
nichd.nih.gov/about/meetings/
2010-retired/ Documents/
Newborn_Research_Agenda.pdf).
A consensus finding was the need
to examine the technical, clinical,
social, and ethical issues related to
sequencing in the newborn period
in unison. Subsequently, the NICHD
and the National Human Genome
Research Institute issued a funding
opportunity to develop a consortium
to explore, in a limited but deliberate
manner, opportunities to use
genomic information for broadening
our understanding of diseases
identified in the newborn period,
in the context of public health NBS
or clinical sequencing of newborns.
The consortium, called Newborn
Sequencing in Genomic Medicine and
Public Health (NSIGHT), is addressing
3 key research questions:

• For disorders currently
screened in newborns, how can
genomic sequencing replicate
or augment known NBS results?
Can sequencing replace current
screening modalities?

• What knowledge could genomic
sequencing provide about

conditions not currently screened
for in newborns?

• What additional clinical
information could be learned from
genomic sequencing relevant to the
clinical care of newborns?
In 2014, 4 groups were funded to
explore newborn sequencing in
different clinical contexts by using
unique study designs (Table 1 and
Fig 1). Each study also included an aim
examining ethical, legal, and social
considerations. This article examines
some of the challenges of newborn
sequencing in 3 distinct clinical
settings, describes the 4 projects,
and puts this research in the context
of current and future strategies for
NBS and sequencing of newborns in
clinical care settings.

CLINICAL SETTINGS FOR NEWBORN
SEQUENCING RESEARCH: DIAGNOSTIC,
PREVENTIVE, AND PREDICTIVE
The setting in which genomic
sequencing is performed affects
its technical performance, yield,
and potential benefits and harms.
In a diagnostic context, newborn
sequencing is much like any other
genetic diagnostic modality,
and the ability to provide a
molecular diagnosis depends on
a number of factors including
genetic architecture, phenotypic
expressivity, locus heterogeneity
and the fraction of cases accounted
for by known disorders, mutational
spectrum, the types of variants that
are detectable by sequencing, and
the quality of the assay performed
in the patient. In contrast, the
application of genomic sequencing
in an asymptomatic newborn
substantially depends on the power
of genotype to predict disease
status in the present or the future.
Thus, a critical question is whether
genomic variant data can be used to
accurately predict disease
when the pretest probability of
disease is low, especially in cases
where there may be no secondary

Downloaded from www.aappublications.org/news by guest on November 8, 2019
2

BERG et al

TABLE 1 NSIGHT Project Overviews
BWH, BCH, Baylor College of
Medicine
Patient cohorts

Sick newborns (ICUs).

Rady, Children’s Mercy
Hospital
Sick newborns (NICU)

Healthy newborns (well
nursery).
Biospecimens

Sequencing

Informatics

Primary results
returned

Secondary results
returned

Whole blood (newborns)
and saliva (newborns and
parents).
Exome sequencing.
Illumina Content Exome.
Illumina HiSeq.
≥100 × mean coverage.
All newborns: analysis
of variants in genes
responsible for childhoodonset disorders (<18 y).
Sick newborns/Lateronset healthy and sick
newborns: indicationbased analysis of all
variants in genes relevant
to the phenotype (if
applicable).
Diagnostic ﬁndings (ICU
patients and others with
clinical indications).
Highly penetrant childhoodonset or childhood
treatable conditions (all
participants).
Carrier status for
childhood-onset
conditions and selected
pharmacogenomics (all
participants).

Whole blood (parent–infant
trios)
WGS
Illumina HiSeq 2500, rapid run
mode

Clinical features translated
into phenotype terms and
differential diagnosis by
Phenomizer (and custom
lists)

Diagnostic or likely diagnostic
ﬁndings

Incidental genetic disease
diagnosis if life-threatening
in childhood

UCSF

University of North Carolina

Deidentiﬁed DBS samples from
California NBS program
Newborn DBS from consenting
individuals with primary
immunodeﬁciency
DBS retrieved from NBS program
biobank

Children affected with known NBS
ﬁndings
Healthy newborns (prenatal
recruitment)

Exome sequencing
Nimblegen v3 capture

Exome sequencing
Agilent V6.0 capture

Illumina HiSeq
40–80 × average coverage
Metabolic disease NBS samples:
blinded assessment as an
initial screen; second-tier
analysis combining genomic,
clinical, and MS/MS data
Immunodeﬁciency cohort:
analysis of genes relevant to
patient’s phenotype

Illumina HiSeq
40–80 × average coverage
All participants: primary analysis
blinded to phenotype

No contact or return of results
for metabolic NBS program
cohort
Offer clinical conﬁrmatory testing
to follow up likely pathogenic
variants for immunodeﬁciency
cohort
None

Childhood-onset medically
actionable conditions (all
participants)
Diagnostic ﬁndings (affected
cohort)
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Cheek swabs

• Known diagnosis cohort:
diagnostic or indication-based
analysis based on phenotypic
ﬁndings

Parents randomly assigned to
decision group can select from
3 categories:
• Childhood-onset non–medically
actionable conditions
• Carrier status for recessive
conditions
• Adult-onset medically actionable
conditions

3

TABLE 1 Continued

Psychosocial and
medical outcomes
research

Other project aims

BWH, BCH, Baylor College of
Medicine
Surveys of parents and
physicians assess impact
of genomic sequencing
across key domains:

Rady, Children’s Mercy
Hospital
Surveys of parents and
physicians assess impact of
genomic sequencing across
key domains:

• Attitudes and preferences.

• Attitudes and preferences

• Health care utilization.

• Health care utilization

• Health behaviors and
intentions.
• Decisional satisfaction.

• Health behaviors and
intentions
• Decisional satisfaction

• Psychological impact.
Psychosocial impact on the
family.

• Psychological impact
• Psychosocial impact on the
family
Correlation of parents’
attitudes about test results
with their health literacy,
genomic literacy, anxiety,
depression, and religiosity
Comparison of rate of
diagnosis and time to
diagnosis in WGS and noWGS groups
Rates and types of
actionability measured

Although Sanger
conﬁrmation is used
for the main project,
the study is exploring
orthogonal sequencing
by 2 NGS methods as an
alternative for variant
conﬁrmation.

gold standard clinical evaluation
by which to validate the genomic
prediction.
Sequencing in a NICU population
of sick infants extends current
molecular diagnostic strategies to a
genomic scale, whereas sequencing
otherwise healthy infants targets the
prevention of future disease and is
more akin to current NBS performed
in a public health setting. Sequence
information could also be used to
guide a patient’s care throughout life
by predicting disease and directing
management strategies for clinical
scenarios that emerge, blending the
predictive, reproductive, diagnostic,
therapeutic, and prognostic
value of genomic information.
The NSIGHT projects differ in the
clinical scenarios in which the use
of genome-scale sequencing is
being studied, spanning the areas
described below.

UCSF

University of North Carolina

Focus groups with:

• Parents of immunodeﬁciency
patients
• Healthy pregnant women
• Obstetric and pediatric
clinicians

Surveys with parents assess
decision-making about genomic
sequencing and its effects on
individual and dyadic parent
outcomes:
• Parents’ collaborative decisionmaking and conﬂict
• Prenatal anxiety (parents of
healthy newborns only)
• Parental bonding with child
• Attitudes and beliefs about
genomic sequencing
• Decision conﬂict and regret
• Test-related and general distress
• Beliefs and concerns about the
child’s future health

Assess suitability of stored DBS
as a source of DNA for deep
sequencing

Diagnostic Sequencing in the NICU
Level III and IV NICUs care for many
neonates with genetic disorders,
including metabolic disorders20 and
congenital malformations.21,22
Indeed, genetic disorders and
congenital anomalies are the
leading cause of death in the
NICU.23 Current approaches for
diagnosis of suspected genetic
disorders in NICU patients include
karyotyping, chromosomal
microarrays, single-gene testing,
and gene panels. In many cases,
the etiologic diagnosis remains
elusive despite several rounds of
genetic testing, and clinical genomescale sequencing is used for only a
small fraction of cases. If genomic
sequencing were used earlier in
the diagnostic process, it could
provide more timely definitive
diagnoses and thereby increase the
precision of treatments, whether

Semiquantitative metric to
determine medical actionability

Electronic decision aid for
parental preference setting

therapeutic or palliative, and
provide answers about prognosis
and family recurrence risk. In
addition, sequence data could aid in
interpretation of the false-positive
NBS results commonly reported
in premature infants because of
their immature organ systems,
liver enzymatic activity, long-term
parenteral nutrition requirement,
and other comorbid conditions.24
Preliminary studies have shown
potential cost reductions resulting
from genomic sequencing in neonates
with genetic disorders.7,25,26
However, uptake has been
impeded by concerns about clinical
interpretation of ambiguous results,
secondary findings and potential
parental anxieties, economic factors
including resistance on the part of
third-party payers in the absence
of definitive data on clinical utility
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FIGURE 1
A, Diagram of the protocol in progress at BWH and BCH, Boston, Massachusetts. Infants are recruited from the well baby nursery at BWH and from
the ICUs at BCH and BWH. After a pre-enrollment session with a study genetic counselor and completion of baseline outcomes, enrolled infants are
randomly assigned to receive NBS and family history or NBS, family history, and exome sequencing. Results are disclosed to the family by a study genetic
counselor and physician, and postdisclosure outcomes are collected. Follow-up is performed at 3 and 10 months after disclosure. Medical, behavioral,
and economic outcomes are collected throughout the study from surveys, medical record reviews, and consultation with the families. B, Diagram of
the protocol in progress at NICUs at Children’s Mercy Hospital, Kansas City (CMH) and Rady Children’s Hospital, San Diego (RCHSD). Eligible patients are
infants <4 months old in whom a clinical genetic test or genetic consult was ordered, or those with 1 major anomaly or 3 minor structural anomalies,
or an abnormal laboratory test suggestive of a genetic disease, or an abnormal response to standard therapy for a major underlying condition. Enrolled
infants are randomly assigned to receive standard diagnostic testing or standard tests and rapid WGS of parent–infant trios. Diagnostic results are
returned. Primary outcome measures are rate of molecular diagnosis in 28 days, time to diagnosis, and whether the diagnosis provided a change in
clinical management. C, Diagram of the NBSeq protocol in progress at UCSF. NBSeq uses archived residual DBS from a very large and diverse population to
examine the diagnostic utility of exome sequencing in 2 parallel projects. For metabolic disorders (left), DBS samples from deidentiﬁed true positives (TP),
false positives (FP), and false negatives (FN) are subjected to exome sequencing, variant calling, and interpretation under blinded models for evaluation of
ﬁrst-tier screening and in conjunction with MS/MS and clinical data for evaluation of second-tier screening. A predetermined list of 93 genes relevant to
the metabolic disorders is the basis for the exome assessment. Consented, identiﬁed patients with immune disorders with no gene identiﬁed (right) also
undergo NBS DBS retrieval and exome sequencing and analysis, in this case with a pipeline restricted to immune system genes. Analysis protocols for both
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and cost-effectiveness, and difficulty
ordering tests due to institutional
concerns over high costs. The process
is also complicated by a need for
detailed phenotypic information
for optimal analysis by diagnostic
laboratories. Provisional genomic
diagnosis of genetic disease is
technically feasible in as little as 26
hours.27,28 However, cost is inversely
related to the turnaround time,
and the optimal balance of cost and
clinical utility is unknown. Although
some aspects of rapid turnaround
time can be improved through
technology, limits imposed by variant
review and clinical interpretation
standards will remain, including the
need for communication between
the clinical team and the laboratory
for clinical genomic assessment.
Parental acceptance of testing, given
the unclear future implications
for insurability and privacy, is not
yet known. Finally, the responses
of neonatologists and parents to
genomic information warrant more
study, and rigorous frameworks for
translating such information into
precision care plans in NICUs remain
to be developed.

Preventive Sequencing in a Public
Health Setting
Current NBS yields few falsenegative results but does incur
substantial numbers of false
positives, with attendant emotional
and financial costs.29 For example,
in a study of 176 186 specimens
screened by MS/MS, there were 51
true positives, 2 false negatives,

and 454 false positives that were
ultimately resolved as nondisease
after referral to a metabolic center.30
Genomic sequencing could function
as a multiplexed second-tier
screen, increasing the specificity of
current MS/MS screening tests by
distinguishing false-positive results
from true disease and aiding in the
differential diagnosis of nonspecific
biochemical profiles. Sequencing
could also confirm conditions
identified through other screening
methods,31–33 aid in providing
prognosis and appropriate
treatment,34–37 determine the
etiology of conditions identified
through point-of-care testing,38 and
provide families with information
about pathogenic variants that
could be used for family testing.
Such analyses could also increase
knowledge of correlations between
genotypes and phenotypes and
might reveal possible genetic
contributions to false positives, such
as abnormal MS/MS screening data
due to carrier status or hypomorphic
variants. These goals will require
longitudinal follow-up to obtain
clinical data and examine genotype–
phenotype correlations to ultimately
determine the predictive capacity
and clinical impact of genetic
variants.
Genomic sequencing could also
be deployed as a first-tier screen,
particularly for rare disorders
that currently lack methods for
conventional biochemical NBS.
In the public health context,

selecting exactly which disorders
to screen for requires careful
consideration of factors such as
age of onset, severity, penetrance,
treatability, confirmatory testing,
and opportunities for surveillance.
Some genetic conditions will fulfill
the original Wilson and Jungner
criteria for screening,39–41 but many
will not. Thus, there is a need for
scalable methods to determine
which conditions would be
appropriate for inclusion in a public
health screening setting. In addition,
the current practice of returning
findings consistent with carrier
status might be unsustainable given
that nearly every person is likely
to be a carrier for a handful of rare
recessive conditions.
A significant challenge in the
use of sequencing for NBS is
the lack of data regarding the
analytic and clinical performance
of sequencing as a predictive
test. Little is known about the
positive or negative predictive
value of genomic sequencing
in asymptomatic people whose
previous probability of disease is
very small. Although it may seem
self-evident that Mendelian diseases
would be best identified from
genetic sequence, this assumption
remains to be demonstrated
and may not be true. Monogenic
illnesses are often influenced by
additional and as-yet-unidentified
genetic or environmental factors,
whereas MS/MS measures
analytes that are typically closer

FIGURE 1 Continued
applications undergo reﬁnement based on integration of observed sensitivity and speciﬁcity with genome analysis tools. Enrollees with immune disorders
can obtain conﬁrmational clinical gene testing, and their assessment of risks, beneﬁts, and uncertainties of exome sequencing for NBS are solicited. D,
Diagram of the North Carolina Newborn Exome Sequencing for Universal Screening protocol in progress at the University of North Carolina at Chapel Hill.
This study is enrolling healthy newborns, identiﬁed prenatally, and children affected with known conditions identiﬁed through standard NBS (metabolic
disorders, hearing loss, pulmonary disorders). Parents use an electronic decision aid in addition to an in-person consultation with a genetic counselor to
determine whether to have their child undergo sequencing. Exome sequencing is performed, with analysis of a panel of genes associated with childhoodonset medically actionable conditions (NGS-NBS) for all participants and indication-based analysis for patients from the diagnosed cohort. Participants
are randomly assigned at the time of return of results. Parents in the control arm receive only the primary diagnostic ﬁndings and NGS-NBS results,
whereas parents in the decision arm will use the electronic decision aid to choose between 3 additional categories of optional genomic information
(adult-onset medically actionable conditions, childhood-onset non–medically actionable conditions, and carrier status for recessive conditions). Parents
will also participate in longitudinal surveys to assess their responses to the genomic information.
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to relevant phenotypes. Even for
the best-studied diseases, there
are substantial challenges in
interpreting rare variants. Variant
selection algorithms that maximize
sensitivity necessarily sacrifice
specificity, leading to increased
false-positive results and
potential downstream harms
due to unnecessary medical
interventions. A strategy of
excluding “variants of uncertain
significance” (which by definition
have poor predictive value) from
genomic screening results may be
necessary. Historically, the focus
of NBS on preventable disorders
has led to low tolerance for falsenegative screening results. With
genomic sequencing it might be
necessary to shift the screening
paradigm from finding all affected
individuals to finding an optimal
proportion of cases for a larger
number of potentially treatable
conditions.

Predictive Sequencing of Newborns
in Genomic Medicine
The broadest vision of genomic
medicine, and potentially the
most challenging for societal and
practical reasons, involves the
use of sequence data to guide a
patient’s care throughout life.
Genomic sequencing reveals
information well beyond the
scope of conventional NBS. Some
of this information could result
in medical action, but most will
not, raising questions of exactly
what information should be
reported and when.42,43 Variant
data could conceivably be held
for future diagnostic analysis
in the event that the patient
develops symptoms of a genetic
condition. Currently, our ability to
interpret genetic variants is largely
confined to simple monogenic
and oligogenic conditions. As
we learn to use multifactorial
models for risk stratification or
management in a clinically useful
way, additional information will

increasingly be available. Within
this spectrum is the potential
for genomic information to alert
clinicians to reconsider the family
history or interpret physical
examination findings in a new
light, and potentially the ability
to benefit other family members
before they develop a disease.
Pharmacogenomic variants could
guide the real-time selection
and dosing of medications,
yielding safer and more effective
treatments. Recessive carrier
traits detected in newborns could
alert parents to genetic risks that
provide information valuable to
reproductive planning. Common
variation for complex conditions
may motivate families to be more
vigilant about diet and other
lifestyle choices. Finally, there is
the potential for voluntary personal
exploration of one’s own genomic
data.
If genomic sequence data are
available, parents will need to
make decisions about whether to
learn about additional categories
of information that may predict
future events about their child with
differing levels of certainty and
ability to intervene, ranging from
childhood-onset conditions that
may not have direct interventions
or preventive measures, adult-onset
medically actionable conditions,
or carrier status for recessive
disorders. Studies suggest that
parents are interested in their
child’s genetic variants, even
when that information has no
defined clinical utility,44 although
these preferences have largely
been elicited in hypothetical
scenarios and may not reflect reallife choices.
Genomic information may enable
families to become aware of
otherwise unsuspected familial risks,
including potentially actionable
adult-onset conditions in the
infant that a parent is unknowingly

carrying. However, some findings
may be at odds with professional
guidance that genetic testing in
asymptomatic minors should
generally be done only when
identification before adulthood
is needed to prevent harm and
directly benefit the child.11,13,17 The
potential to query genome-scale data
in children for secondary findings
has elicited vigorous debate over
the ethical boundaries of return
of results. The argument has been
made that benefit to family (eg,
a parent who is unknowingly at
risk) may be a valid consideration
in decisions regarding return of
results for actionable adult-onset
conditions in children.45,46 Genomescale sequencing and analysis in
newborns would probably require
modification of current informed
consent procedures41,47 compared
with a targeted screen focusing on
a restricted number of conditions.
If implemented across the entire
population, genomic sequencing
would fundamentally alter
contemporary public health NBS
procedures, necessitating innovative
approaches to facilitate parental
decision-making. Alternatively,
such testing could be implemented
through voluntary, out-of-pocket
testing.
Expanding genomic sequencing
in newborns to include a broad
range of conditions demands a
close partnership between clinical
providers and parents, similar
to other areas of medicine in
which shared decision-making
is becoming the norm.48,49
Determining criteria for disclosure
of information will be a challenge
for clinicians and policymakers
and will require development
of decisional supports to help
parents determine the information
they want to learn.50 The clinical
interactions needed for support of
parental decision-making would
move this activity beyond the realm
of current public health service
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provision and into the clinical
domain. Workforce shortages
may present significant obstacles
if genome-scale sequencing
were to become widely available
in the public health setting,51
suggesting that new and more
scalable materials and procedures
for communicating the potential
benefits and risks of learning such
information would need to be
developed, validated, and
deployed. Systems may need to be
established that enable parents
to request certain results from
their child’s genomic information
over time, allowing them to decide
iteratively as their values and
perceptions of risk change or as
their child attains an age to assent
or consent.

The complexities of genomic result
interpretation currently demand
trained geneticists and genetic
counselors to provide guidance and
follow-up management. As genomic
medicine becomes more mainstream
in health care, a broader range of
health care providers will need to
interact with genetic information,
which is likely to be increasingly
viewed as 1 of many risk factors
influencing future conditions;
reports will have to be constructed
with clarity that makes them useful
for pediatricians and primary care
providers. The potential use of this
type of genomic information over
time would necessitate development
of new infrastructure to manage
reporting, reanalysis, storage,
and integration with electronic
health records. Such data could
be used for iterative phenotyping
of the individual to define the
clinical relevance of genetic
variants. However, thresholds for
reporting or acting on potentially
relevant variants would have to
be calibrated against the possible
harms of false-positive results or
overdiagnosis, which would lead to
unnecessary, dangerous, or costly

medical treatments.52 The benefits
of detecting true positives must
therefore be balanced against the
magnitude of harms.

NSIGHT RESEARCH GROUPS, STUDY
DESIGNS, AND KEY QUESTIONS BEING
ADDRESSED
Each of the 4 members of the
NSIGHT Consortium independently
designed and implemented
study designs that focus on
somewhat different populations
and research questions (Fig 1 and
Table 1).
Genome Sequence-Based
Screening for Childhood Risk
and Newborn Illness project
(Fig 1A), led by Brigham and
Women’s Hospital (BWH) and
Boston Children’s Hospital (BCH)
at Harvard Medical School and
by Baylor College of Medicine,
is a randomized controlled trial
assessing the impact of providing
genomic sequencing information
to parents and physicians of
newborns (clinicaltrials.gov
identifier NCT02422511). The
study is enrolling a cohort of
healthy newborns approached in
the postpartum period from the
BWH Well Baby Nursery and a
cohort of sick newborns from the
BWH NICU and the ICUs at BCH.
Within each cohort newborns
are randomly assigned to either
the control arm (conventional
NBS results and a detailed family
history) or the experimental
arm (genomic sequencing in
addition to conventional NBS and
a detailed family history). Parents
and physicians are surveyed to
assess the impact of the genomic
information across several key
domains including attitudes and
preferences, health care utilization,
health behaviors and intentions,
decisional satisfaction, and
psychosocial impact on the
family.53

The Clinical and Social Implications
of 2-Day Genome Results in
Acutely III Newborns project, led
by Rady Children’s Institute for
Genomic Medicine and Children’s
Mercy Hospital, studies the use of
rapid whole genome sequencing
(WGS) at 2 large level-IV NICUs
(∼1000 admissions per year)
in children’s hospitals (Fig 1B).
WGS was adapted for diagnosis
of rare genetic diseases in NICUs,
including shortening the minimum
time to provisional diagnosis to
26 hours, increasing the analytic
sensitivity and specificity of
variant detection to >99.5%,
and gaining US Food and Drug
Administration approval to report
a provisional diagnosis verbally to
an attending neonatologist if death
was imminent and the diagnosis
would inform implementation of
a treatment that could change the
outcome.27,28 The current study is a
prospective, randomized controlled
trial of the diagnostic utility, costeffectiveness, and psychosocial
implications of rapid WGS at the 2
NICUs (clinicaltrials.gov identifier
NCT02225522). As part of this
study, doctors and parents are
surveyed about their perceptions
of the risks and benefits of rapidly
obtaining WGS results.
The goal of the Sequencing of
Newborn Blood Spot DNA to
Improve and Expand Newborn
Screening (NBSeq) project, led by
the University of California, San
Francisco (UCSF) and collaborating
institutions, is to evaluate the
potential application of exome
sequencing to public health NBS
by using dried blood spots (DBS)
(Fig 1C). The project explores the
feasibility of exome sequencing to
augment or replace current
MS/MS technologies in NBS. Exome
sequencing is performed at UCSF
on deidentified archival DBS from
all California newborns found to
have metabolic disorders in the
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TABLE 2 Cross-Consortium Working Groups
Ethical, Legal, Economic, and
Social Issues
Key questions
• Differences in perceptions
of beneﬁts and risks of
sequencing between
symptomatic and
asymptomatic populations
• Parent willingness to accept
sequencing and factors
associated with parents’
decisions
• Extent to which parents are
willing to accept uncertainties
inherent in test interpretation

Common Data Elements
Key questions
• Identify common data elements
in the NSIGHT projects to
be collected systematically
across the consortium
• Collaboration with NBSTRN to
use LPDR for individual cohort
and combined cohort analysis
where applicable
• Deﬁne data elements to be
shared more broadly, in a
deidentiﬁed fashion, with
other researchers in the
NBSTRN

Outcomes and Measure
Key questions
• Identify common outcome
measures in the NSIGHT
projects to be collected
systematically across the
consortium
• Considerations of the overall
cost/beneﬁt ratio of newborn
sequencing

• How key stakeholders make
decisions about whom to test,
how to share results, under
what circumstances, and with
what goals
• Public policy regarding use
of genome sequencing as
part of mandated screening
programs
LPDR, Longitudinal Pediatric Data Resource (https://www.nbstrn.org/research-tools/longitudinal-pediatric-data-resource).

past decade, as well as samples
that were false positives on the
MS/MS screening. Sequence data
from newborn DBS54 are also being
interrogated in a cohort of 50
patients who have been clinically
diagnosed with immunodeficiency
disorders to determine whether
sequencing DBS as part of NBS
could facilitate early diagnosis
and optimal management of non–
severe combined immunodeficiency
immune defects. Stakeholder views,
perspectives, and value preferences
about the potential expansion of
NBS are being evaluated through
focus groups.55 In addition, legal and
constitutional issues surrounding
the potential use of genomescale analysis in NBS are being
examined.56
The North Carolina Newborn Exome
Sequencing for Universal Screening
study at the University of North
Carolina at Chapel Hill evaluates
exome sequencing from saliva
samples in 2 groups: children and

infants affected with conditions
identified through standard NBS
and a cohort of healthy newborns
whose parents are approached
for participation prenatally (Fig
1D). Parents will use an electronic
decision aid to assist in decisions
about exome sequencing.57 After
providing informed consent at an
in-person study visit, those who
accept sequencing will receive
results from a “next-generation
sequencing newborn screening
(NGS-NBS)” panel of genes
implicated in childhood-onset
medically actionable conditions.58
Parents will also be enrolled in
a randomized trial of decisionmaking regarding whether to
learn about 3 types of additional
genomic findings in their child
by using the electronic decision
aid (clinicaltrials.gov identifier
NCT02826694). The study seeks to
understand how parents think about
and consider different categories of
information,59 and, combined with
longitudinal quantitative surveys,

the study will reveal the spectrum
of results parents decide to learn,
issues surrounding returning
these findings, and consequences
of decision-making and results
disclosure.

CROSS-CUTTING CONSORTIUM
ACTIVITIES
Although the research projects
address distinct research questions
and have unique study designs,
the 4 NSIGHT groups participate
in consortium activities that build
on the strengths at each site and
harmonize data collection to
improve cross-cutting analysis
(Table 2). An ethical, legal, and
social implications workgroup
brings together the perspectives
of each project regarding the
responses of clinicians, families,
payers, and other stakeholders;
parental informed consent and
decision-making; and implications
for public health NBS programs.19,60
The Common Data Elements
workgroup is charged with creating
a common set of data elements
collected across the 4 research
groups to enable data sharing
and combined data analysis. The
Outcomes and Measures workgroup
examines the standardized
instruments being used by each
group to assess stakeholder
responses to newborn sequencing
to facilitate cross-consortium
analyses. The NSIGHT Consortium is
working closely with the Newborn
Screening Translational Research
Network (NBSTRN) Coordinating
Center, housed at the American
College of Medical Genetics
and Genomics. The NBSTRN,
created as part of the NICHD’s
Hunter Kelly Newborn Screening
Research Program to create a
shared research infrastructure
to support NBS researchers,
provides a mechanism to increase
understanding of conditions that
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are currently part of routine NBS
or may be future candidates for
screening. The NBSTRN resources,
tools, and network of experts are
used in population-based pilots of
new screening technologies and
natural history studies of screened
conditions. NSIGHT Consortium
investigators also maintain close
ties with other National Institutes of
Health–funded consortia including
the Clinical Sequencing Exploratory
Research consortium61 and
Clinical Genome Resource
consortium.62

CONCLUSIONS
Data gathered from the projects
in the NSIGHT Consortium
will address technical, clinical,
and ethical questions that
are fundamental to the future
consideration of sequencing
in newborns. The projects will
determine the feasibility and
utility of this technology in critical
care and public health settings.

Design and implementation of
rapid high-throughput methods
will be essential to maximize
the benefit of sequencing for
certain conditions in the neonatal
population. Longitudinal follow-up
of parents will allow the study
of parental decision-making,
measure parental preferences in
real-world settings, and assess
test-related stress or anxiety.
Medical outcomes of the children
who undergo sequencing will need
to be monitored over many years.
Ultimately, these data will aid in
the development of best clinical
practices and provide guidance on
the implementation of sequencing
in newborns. Although genomic
sequencing will expand our ability
to diagnose conditions and offer
personalized treatments, health
care providers and public health
entities must be good stewards of
this technology, ensuring careful
attention to ethical standards
and evidence-based outcomes in
making recommendations about its
use.

ABBREVIATIONS
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BWH: Brigham and Women’s
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MS/MS: tandem mass
spectrometry
NBS: newborn screening
NBSeq: Sequencing of Newborn
Blood Spot DNA to
Improve and Expand
Newborn Screening
NBSTRN: Newborn Screening
Translational Research
Network
NGS-NBS: next-generation
sequencing newborn
screening
NICHD: Eunice Kennedy Shriver
National Institute of
Child Health and Human
Development
NSIGHT: Newborn Sequencing in
Genomic Medicine and
Public Health
UCSF: the University of
California, San Francisco
WGS: whole genome sequencing
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